HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100CompaniesDeal TrackerResearch
Biotech

BioMarin Pharmaceutical Inc.

2
Articles
Competitor
Top Role
Feb 27, 2026
First Mention
Mar 24, 2026
Last Mention
1.23
Relevance Score

Coverage Timeline

March 2026
CRISPR Therapeutics’ CS37 in Hemophilia B: Breakthrough Candidate or Regulatory Gamble? Pipeline Competitor
Mar 24, 2026
Regulatory bar-raising after the launches of Hemgenix and BioMarin’s Roctavian means early efficacy figures aren’t enough.
February 2026
Amgen’s $27.8B Horizon Buy: Betting Big on Rare Diseases, Revenue Multiples, and Pipeline Synergies Deals Competitor
Feb 27, 2026
For context, AstraZeneca’s Alexion deal landed at 10x revenue back in 2021, and BioMarin, another rare disease player, still trades closer to the 7-9x range.
Related Companies
CSL Limited
1 shared
Cigna Corporation
1 shared
CRISPR Therapeutics AG
1 shared
Celgene Corporation
1 shared
Horizon Therapeutics plc
1 shared
Amgen Inc.
1 shared
AstraZeneca PLC
1 shared